The Inflammation Research Association is pleased to sponsor a symposium entitled:

Paradigms in Inflammation Research: New Ways of Thinking About and Treating Disease

The Inflammation Research Association announces a one-day conference in Seattle on September 16. The meeting will highlight emerging local research into the underpinnings of immunologic disease and showcase local companies transforming therapy with AI platforms, cellular therapies and more.

REGISTRATION FEES: $125 Current IRA Member, $175 Non-Member. Both include 2026 IRA Membership

WHEN & WHERE:
Tuesday, September 16, 2025, 8:00 AM – 5:30 PM
UW Medicine, South Lake Union Campus
Orin Smith Auditorium
850 Republican Street
Seattle, WA 98109
Map and Directions

CONFIRMED KEYNOTE SPEAKER:

Tomas Mustelin, MD, PhD
Head, Division of Rheumatology, UW Medicine
Title – Old and new ideas about autoimmune diseases (KEYNOTE)

ADDITIONAL CONFIRMED SPEAKERS TO DATE:

Marc Gavin, PhD
Head of Immunology, InduPro
Title – Remixing the immune synapse for the development of novel PD-1 targeting strategies

Randolph Lopez, PhD
CTO & Co-Founder, A-Alpha Bio
Title – Improving expression and stability of immunocytokine therapeutics

Teal Hallstrand, MD, MPH
Professor of Medicine, Director of Airway Biology, Center for Lung Biology, UW Medicine
Title – The evolution of asthma therapy towards greater precision

S. Alice Long, PhD
Member, Benaroya Research Institute
Title – Exhausting T cells to treat T1D

Christian Lood, PhD
Associate Professor, UW Medicine, Division of Rheumatology
Title – Targeting and monitoring neutrophil-mediated inflammation

Erik Procko, PhD
Chief Scientific Officer, Cyrus Biotechnology
Title – An engineered lgG protease for rapid, deep, and sustained depletion of autoantibodies

Alan Wahl, PhD
CEO, D Biotherapeutics
Title – Targeting CD180 for the treatment of autoimmune and inflammatory disease

Mark Gillespie, PhD
Assistant Investigator, Allen Institute of Immunology
Title – Preclinical immune drivers of Rheumatoid Arthritis

Stefanie Mandl-Cashman, PhD
CSO, Indapta Therapeutics
Title – Scientific rationale for g-NK cell therapy in autoimmune disease